학술논문
Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study.
Document Type
Academic Journal
Author
Zaballa ME; Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.; Perez-Saez J; Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.; de Mestral C; Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.; University Centre for General Medicine and Public Health, University of Lausanne, Lausanne, Switzerland.; Pullen N; Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.; Lamour J; Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.; Turelli P; School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.; Raclot C; School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.; Baysson H; Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.; Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Pennacchio F; Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.; Villers J; Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.; Duc J; School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.; Richard V; Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.; Dumont R; Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.; Semaani C; Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.; Loizeau AJ; Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.; Graindorge C; Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.; Lorthe E; Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.; Balavoine JF; Department of Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Pittet D; Department of Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Infection Control Program and World Health Organization Collaborating Centre on Patient Safety, Geneva University Hospitals, Geneva, Switzerland.; Schibler M; Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals, Geneva, Switzerland.; Vuilleumier N; Department of Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals, Geneva, Switzerland.; Chappuis F; Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Division and Department of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.; Kherad O; Department of Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Division of Internal Medicine, Hôpital de la Tour, Geneva, Switzerland.; Azman AS; Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.; Posfay-Barbe KM; Department of Woman, Child, and Adolescent Medicine, Geneva University Hospitals, Geneva, Switzerland.; Department of Pediatrics, Gynecology & Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Kaiser L; Department of Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals, Geneva, Switzerland.; Division of Infectious Diseases, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.; Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland.; Trono D; School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.; Stringhini S; Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.; University Centre for General Medicine and Public Health, University of Lausanne, Lausanne, Switzerland.; Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Guessous I; Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Division and Department of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.
Source
Publisher: [Oxford] Country of Publication: England NLM ID: 101777707 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-7762 (Electronic) Linking ISSN: 26667762 NLM ISO Abbreviation: Lancet Reg Health Eur Subsets: PubMed not MEDLINE
Subject
Language
English
Abstract
Background: More than two years into the COVID-19 pandemic, most of the population has developed anti-SARS-CoV-2 antibodies from infection and/or vaccination. However, public health decision-making is hindered by the lack of up-to-date and precise characterization of the immune landscape in the population. Here, we estimated anti-SARS-CoV-2 antibodies seroprevalence and cross-variant neutralization capacity after Omicron became dominant in Geneva, Switzerland.
Methods: We conducted a population-based serosurvey between April 29 and June 9, 2022, recruiting children and adults of all ages from age-stratified random samples of the general population of Geneva, Switzerland. We tested for anti-SARS-CoV-2 antibodies using commercial immunoassays targeting either the spike (S) or nucleocapsid (N) protein, and for antibody neutralization capacity against different SARS-CoV-2 variants using a cell-free Spike trimer-ACE2 binding-based surrogate neutralization assay. We estimated seroprevalence and neutralization capacity using a Bayesian modeling framework accounting for the demographics, vaccination, and infection statuses of the Geneva population.
Findings: Among the 2521 individuals included in the analysis, the estimated total antibodies seroprevalence was 93.8% (95% CrI 93.1-94.5), including 72.4% (70.0-74.7) for infection-induced antibodies. Estimates of neutralizing antibodies in a representative subsample (N = 1160) ranged from 79.5% (77.1-81.8) against the Alpha variant to 46.7% (43.0-50.4) against the Omicron BA.4/BA.5 subvariants. Despite having high seroprevalence of infection-induced antibodies (76.7% [69.7-83.0] for ages 0-5 years, 90.5% [86.5-94.1] for ages 6-11 years), children aged <12 years had substantially lower neutralizing activity than older participants, particularly against Omicron subvariants. Overall, vaccination was associated with higher neutralizing activity against pre-Omicron variants. Vaccine booster alongside recent infection was associated with higher neutralizing activity against Omicron subvariants.
Interpretation: While most of the Geneva population has developed anti-SARS-CoV-2 antibodies through vaccination and/or infection, less than half has neutralizing activity against the currently circulating Omicron BA.5 subvariant. Hybrid immunity obtained through booster vaccination and infection confers the greatest neutralization capacity, including against Omicron.
Funding: General Directorate of Health in Geneva canton, Private Foundation of the Geneva University Hospitals, European Commission ("CoVICIS" grant), and a private foundation advised by CARIGEST SA.
Competing Interests: DT is a founder and co-chair of the Scientific Advisory Board of Aerium Therapeutics, holds stock in that company, and has two patents pending for monoclonal antibodies against SARS-CoV-2. KMPB is a member of the Advisory Boards for pneumococcal vaccine and varicella vaccine at MSD. All other authors declare that they have no competing interests.
(© 2022 The Authors.)
Methods: We conducted a population-based serosurvey between April 29 and June 9, 2022, recruiting children and adults of all ages from age-stratified random samples of the general population of Geneva, Switzerland. We tested for anti-SARS-CoV-2 antibodies using commercial immunoassays targeting either the spike (S) or nucleocapsid (N) protein, and for antibody neutralization capacity against different SARS-CoV-2 variants using a cell-free Spike trimer-ACE2 binding-based surrogate neutralization assay. We estimated seroprevalence and neutralization capacity using a Bayesian modeling framework accounting for the demographics, vaccination, and infection statuses of the Geneva population.
Findings: Among the 2521 individuals included in the analysis, the estimated total antibodies seroprevalence was 93.8% (95% CrI 93.1-94.5), including 72.4% (70.0-74.7) for infection-induced antibodies. Estimates of neutralizing antibodies in a representative subsample (N = 1160) ranged from 79.5% (77.1-81.8) against the Alpha variant to 46.7% (43.0-50.4) against the Omicron BA.4/BA.5 subvariants. Despite having high seroprevalence of infection-induced antibodies (76.7% [69.7-83.0] for ages 0-5 years, 90.5% [86.5-94.1] for ages 6-11 years), children aged <12 years had substantially lower neutralizing activity than older participants, particularly against Omicron subvariants. Overall, vaccination was associated with higher neutralizing activity against pre-Omicron variants. Vaccine booster alongside recent infection was associated with higher neutralizing activity against Omicron subvariants.
Interpretation: While most of the Geneva population has developed anti-SARS-CoV-2 antibodies through vaccination and/or infection, less than half has neutralizing activity against the currently circulating Omicron BA.5 subvariant. Hybrid immunity obtained through booster vaccination and infection confers the greatest neutralization capacity, including against Omicron.
Funding: General Directorate of Health in Geneva canton, Private Foundation of the Geneva University Hospitals, European Commission ("CoVICIS" grant), and a private foundation advised by CARIGEST SA.
Competing Interests: DT is a founder and co-chair of the Scientific Advisory Board of Aerium Therapeutics, holds stock in that company, and has two patents pending for monoclonal antibodies against SARS-CoV-2. KMPB is a member of the Advisory Boards for pneumococcal vaccine and varicella vaccine at MSD. All other authors declare that they have no competing interests.
(© 2022 The Authors.)